386 related articles for article (PubMed ID: 34850445)
1. The microbial metabolome in metabolic-associated fatty liver disease.
Li M; Rajani C; Zheng X; Jia W
J Gastroenterol Hepatol; 2022 Jan; 37(1):15-23. PubMed ID: 34850445
[TBL] [Abstract][Full Text] [Related]
2. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease.
Jia W; Rajani C
Adv Exp Med Biol; 2018; 1061():95-110. PubMed ID: 29956209
[TBL] [Abstract][Full Text] [Related]
3. Mining Gut Microbiota From Bariatric Surgery for MAFLD.
Wu WK; Chen YH; Lee PC; Yang PJ; Chang CC; Liu KL; Hsu CC; Huang CC; Chuang HL; Sheen LY; Liu CJ; Wu MS
Front Endocrinol (Lausanne); 2021; 12():612946. PubMed ID: 33897617
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
Cornejo-Pareja I; Amiar MR; Ocaña-Wilhelmi L; Soler-Humanes R; Arranz-Salas I; Garrido-Sánchez L; Gutiérrez-Repiso C; Tinahones FJ
J Gastroenterol; 2024 Apr; 59(4):329-341. PubMed ID: 38265508
[TBL] [Abstract][Full Text] [Related]
5. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome.
Abenavoli L; Scarlata GGM; Scarpellini E; Boccuto L; Spagnuolo R; Tilocca B; Roncada P; Luzza F
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984595
[TBL] [Abstract][Full Text] [Related]
6. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
[TBL] [Abstract][Full Text] [Related]
7. Microbial Dysbiosis Linked to Metabolic Dysfunction-Associated Fatty Liver Disease in Asians:
Yuan H; Wu X; Wang X; Zhou JY; Park S
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396863
[TBL] [Abstract][Full Text] [Related]
8. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated fatty liver disease (MAFLD) as a more accurate name for NAFLD - common aspects of pathogenesis.
Nováková B
Cas Lek Cesk; 2022; 161(2):65-71. PubMed ID: 35728960
[TBL] [Abstract][Full Text] [Related]
10. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
Barchetta I; Cimini FA; Cavallo MG
Nutrients; 2020 Oct; 12(11):. PubMed ID: 33126575
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease.
Oh JH; Lee JH; Cho MS; Kim H; Chun J; Lee JH; Yoon Y; Kang W
Nutrients; 2021 Mar; 13(3):. PubMed ID: 33801023
[TBL] [Abstract][Full Text] [Related]
13. Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota.
Drożdż K; Nabrdalik K; Hajzler W; Kwiendacz H; Gumprecht J; Lip GYH
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010976
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.
Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060
[TBL] [Abstract][Full Text] [Related]
15. Mapping the human oral and gut fungal microbiota in patients with metabolic dysfunction-associated fatty liver disease.
Niu C; Tu Y; Jin Q; Chen Z; Yuan K; Wang M; Zhang P; Luo J; Li H; Yang Y; Liu X; Mao M; Dong T; Tan W; Hu X; Pan Y; Hou L; Ma R; Huang Z
Front Cell Infect Microbiol; 2023; 13():1157368. PubMed ID: 37180439
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of gut microbiota in patients with metabolic associated fatty liver disease.
Yang C; Xu J; Xu X; Xu W; Tong B; Wang S; Ji R; Tan Y; Zhu Y
Sci Rep; 2023 Jun; 13(1):9988. PubMed ID: 37340081
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.
Ghoshal UC; Goel A; Quigley EMM
Indian J Gastroenterol; 2020 Feb; 39(1):9-21. PubMed ID: 32291578
[TBL] [Abstract][Full Text] [Related]
18. [Microbiome & NASH - partners in crime driving progression of fatty liver disease].
Wree A; Geisler LJ; Tacke F
Z Gastroenterol; 2019 Jul; 57(7):871-882. PubMed ID: 31288283
[TBL] [Abstract][Full Text] [Related]
19. The role of the microbiome in NAFLD and NASH.
Kolodziejczyk AA; Zheng D; Shibolet O; Elinav E
EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30591521
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
